A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia

Yukio Kobayashi1 · Toru Sakura2 · Shuichi Miyawaki3 · Kazuyuki Toga4 · Shinji Sogo5 · Yuji Heike6,7

Abstract Wilms’ tumor 1 (WT1) is a promising target of new immunotherapies for acute myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide derived from the WT1 protein. OCV-501 induced OCV-501-specific Type 1 T-helper (Th1) responses dose-dependently and stimulated helper activity of the specific Th1 cells in peripheral blood mononuclear cells from healthy donors. OCV-501 also enhanced the increase in WT1-killer peptide-specific cytotoxic T lymphocytes. OCV-501 stimulated the OCV-501-specific Th1 clones in an HLA class-II restricted manner and formed a complex with HLA class-II protein. OCV-501-specific Th1 clones demonstrated significant OCV-501-specific cytolytic activity against OCV-501-pulsed B-lymphoblastoid cell line cells. Based on the pre-clinical results, phase 1 clinical trial was conducted. The result of this trial suggested that the subcutaneous administration of OCV-501 once weekly for 4 weeks at doses of 0.3, 1, and 3 mg in older patients with AML during complete remission was safe and well tolerated. The maximum tolerated dose was considered to be ≥3 mg. Of the nine subjects enrolled, neither relapse nor blast cells were observed during the study. Immunological responses were observed in OCV-501-specific delayed-type hypersensitivity test. This trial was registered at http://www.clinicaltrials.gov as NCT 01440920.

Keywords OCV-501 · Acute myeloid leukemia · WT1 · Helper peptide · Immunotherapy · Cancer vaccine

Abbreviations
AML  Acute myeloid leukemia
B-LCL  B-lymphoblastoid cell line
CR  Complete remission
DLT  Dose-limiting toxicity
DTH  Delayed-type hypersensitivity
MTD  Maximum tolerated dose
TEAEs  Treatment-emergent adverse events
Th1  Type 1 T-helper
WT1  Wilms’ tumor 1
Introduction

Acute myeloid leukemia (AML) is the most common leukemia in older adults. Chemotherapy is a standard treatment for patients with AML and is usually divided into remission induction and consolidation therapy. Treatment efficacy and tolerability deteriorate markedly with advancing age. Complete remission (CR) rates in younger patients exceeded 70%, but declined to 50% in older patients [1]. One of the major obstacles to curing AML, particularly in older patients, is its propensity to relapse after the achievement of CR with chemotherapy or hematopoietic stem-cell transplantation [2]. Therefore, new therapeutic strategies for preventing relapse after consolidation therapy for AML are urgently needed. The graft versus leukemia effect associated with allogeneic hematopoietic stem cell transplantation strongly suggests that immunotherapy is a promising AML treatment [3, 4]. Recent studies have identified several promising AML antigens as targets of immunotherapy [4]. Wilms’ tumor 1 (WT1) antigen is acknowledged as a top-ranked among 75 cancer antigens [5].

The WT1 was first isolated from Wilms’ tumor, a cancer of the kidney in children, as a tumor suppressor gene [6]. Extensive investigations by Oka and Sugiyama revealed that WT1 possesses oncogenic function and is strongly expressed in hematological malignancies and some solid cancers [7–9]. High-level expression of WT1 was an accurate predictor of poor disease-free and overall survival rates [10]. The WT1 antisense oligomers [11] and WT1-specific CTLs [12] inhibited the growth of leukemic cells without affecting normal cells, suggesting that WT1 plays an important role in leukemogenesis.

Clinical trials of cancer vaccines using synthetic WT1 peptide have been conducted in patients with AML as well as with solid tumors for more than a decade and some clinical responses and benefits have been observed [13–15]. The earlier generation of WT1 peptide vaccines was the HLA class I-binding short peptide (killer peptide), consisting of 8–9 amino acids, which can be easily synthesized as a drug candidate. CD8+ T cells recognize tumor-associated antigen (TAA)-derived killer peptides presented on cancer cell surfaces in association with HLA class I molecules, leading to cancer cell death [16, 17]. Recently, it was reported [18, 19] that the beneficial effects derived from WT1-killer peptides were short because of the induction of T cell tolerance. Repeated delivery of killer peptides led to the rapid loss of high-avidity peptide-specific CD8+ CTLs and CD4+ Type 1 T-helper (Th1) cells are required for secondary expansion and memory in CD8+ CTLs [20, 21]. Therefore, to overcome poor clinical outcomes of cancer vaccination, helper peptides that elicit CD4+ Th1 cells should be considered [22, 23].

OCV-501 (developed by Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) is a synthetic peptide consisting of the natural sequence derived from the WT1 gene product, without any modification or combination with other peptide sequences [24]. It can induce specific CD4+ Th1 cells from peripheral blood mononuclear cells (PBMC) from healthy donors, but does not directly induce CD8+ CTL with killer epitope-specificity (e.g. WT1-126, WT1-235, etc.). Therefore, OCV-501 is an HLA class II-restricted WT1-helper peptide for therapeutic cancer vaccine. Here, we report in vitro pharmacological properties of OCV-501 and the phase 1 clinical trial in older patients with AML.

Materials/patients and methods

OCV-501 used in this study was synthesized in Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (KRYFKLSH-LQMHSRKH, purity >95% as acetic acid salt).

Pre-clinical pharmacology

Induction and activation of OCV-501-specific Th1 cells from peripheral blood mononuclear cells

Induction of OCV-501-specific T lymphocytes was performed according to a previously reported method [24]. Briefly, after written informed consent, human PBMC were isolated from 20 healthy donors with one or more of the HLA class II types (DRB1*04:05/15:01/15:02 and DPB1*09:01/05:01) by gradient centrifugation on Lymphoprep (Axis Shield Diagnostics Ltd., Dundee, Scotland). PBMC were cultured with medium mixture of 45% RPMI-1640 (Sigma–Aldrich, St. Louis, USA)+45% AIM-V (Thermo Fisher Scientific, Waltham, USA)+10% human AB serum (MP Biomedicals Inc., Santa Ana, US) containing 20 μg/mL of OCV-501 (purity ≥98%) and 10 ng/mL of IL-7 (PeproTech, Inc., Rocky Hill, USA) at 37°C, 5% CO2 (day 0), and the control group was cultured without OCV-501. PBMC were restimulated and cultured with OCV-501-pulsed antigen-presenting cell (APC), which were prepared from PBMC pre-cultured with 20 μg/mL of OCV-501 followed by 50 μg/mL of mytomycin (Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan) in the presence of IL-7 (day 7). From day 9, IL-2 (PeproTech, Inc., Rocky Hill, USA) was added to the culture (final concentration 20 U/mL) at 2-day intervals. The resulting OCV-501-specific Th1 cells were counted by intracellular IFN-γ staining on days 0, 7, and 14. At each time point, the harvested cells were restimulated with/without OCV-501 for 6 h, followed by 2 h incubation with Brefeldin A (BioLegend Inc., San Diego, USA), because the cultured T cells were HLA class II*.
The cells were stained with PE-anti-human CD4 Ab and FITC-anti-human CD8 Ab (Beckman Coulter Inc., Brea, USA). Intracellular IFN-γ staining was then performed according to the manufacturer’s protocol using the BD Cytotox/Cytoperm Fixation/Permeabilization Kit (BD Biosciences, Franklin Lakes, USA). Finally, stained cells were analyzed using Coulter EPICS XL-MCL Flow Cytometer (Beckman Coulter Inc., Brea, USA). Proportions of CD4+/intracellular IFN-γ + cells (total CD4+ cell number) × 100, and OCV-501-specific Th1 cells (%) [B] were calculated as follows: [A] = [number of CD4+ intracellular IFN-γ cells]/[total CD4+ cell number] × 100, and [B] = [OCV-501 restimulated] − [A] [Background: Solvent restimulated], respectively. For HLA class II-blocking assay, the OCV-501-specific T cells induced by a 14-day culture of PBMC with OCV-501 were pre-treated with 10 μg/mL of each antibody; anti-HLA-DR Ab (BD Biosciences, Franklin Lake, USA), anti-HLA-DQ Ab (Beckman Coulter Inc., Brea, USA), or control Ab (mouse IgG2a) (BioLegend, San Diego, USA) for 30 min, and cultured with/without OCV-501 for 24h. Then, produced IFN-γ was measured using BD OptEIA ELISA Sets (human IFN-γ) (BD Biosciences, Franklin Lakes, USA) and VMAX Microplate Reader (Molecular Devices, Sunnyvale, USA). The dose-dependent activation with OCV-501 was evaluated by restimulation of the cultured cells (OCV-501-induced, day 14) with a dose series of OCV-501 (0.1, 1, 10, 100, and 1000 μg/mL).

CD8+ killer T cell activation by OCV-501-specific Th1 cell

OCV-501-specific Th1 cells and WT1-killer peptide-specific CTLs were induced by 14 days of co-culture of human PBMC from healthy donors with both HLA class I (A*02:01 or A*24:02) and one or more of the HLA class II types (DRB1*04:05/15:01/15:02 and DPB1*09:01/05:01) with medium containing 20 μg/mL of OCV-501 and either 20 μg/mL of WT1-killer peptide WT1-126 [16] (RMFP-NAPYL, purity ≥ 98%, Otsuka Pharmaceutical Co., Ltd.) or WT1-235mu [25] (CYTWNQMNL, purity ≥ 94%, Otsuka Pharmaceutical Co., Ltd.). The cultured T cells were then plated and cultured with/without OCV-501 in the presence of WT1-killer peptide-pulsed APC (day 0). The number of WT1-killer peptide-specific CTLs was measured by tetramer assay. Briefly, harvested cells (day 0 or day 5) and PE-conjugated tetramer; WT1A*0201 tetramer (for detection of WT1-126-specific CTL), WT1 (mutant) A*2402 tetramer (for detection of WT1-235mu-specific CTL), A*0201 negative tetramer or A*2402 negative tetramer (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan), were mixed vigorously and incubated for 30 min. FITC-conjugated anti-human CD45 Ab (Beckman Coulter Inc., Brea, US) and PC5-conjugated anti-human CD8 Ab (0.5 μL) were added, mixed vigorously and incubated for 15 min. Cells were re-suspended and counted by Coulter EPICS-XL MCL Flow Cytometer.

HLA class II-restriction and cytolytic activity of OCV-501-specific Th1 clones

OCV-501-specific Th1 clones (CloneR45-1 and CloneP51-5) were established using the induction/cloning culture with OCV-501 from the PBMC of 2 healthy donors as described above. Each Th1 clone bearing HLA-DRB1*04:05 or HLA-DRB1*04:05/05:01 was stimulated by various B-lymphoblastoid cell lines (B-LCL) (RIKEN Cell Bank, Tsukuba, Japan) as APC, which were pulsed with/without OCV-501. Features of HLA class II of the B-LCL used were DRB1*04:05(+), DRB1*04:05(-), DRB1*05:01(+), and DRB1*05:01(-). After APC stimulation, the concentrations of IFN-γ were measured by ELISA.

Complex formation of OCV-501 with HLA class II proteins such as DRB1*01:01, DRB1*01:04:05, DRB1*08:03, DRB1*09:01, DRB1*15:01, DRB1*15:02, DRB4*01:01 was examined by HPLC method according to the method reported by Sato [26]. Briefly, folding reaction buffer solution was prepared by combining the HLA proteins with OCV-501, positive control peptide; HLA-DRB1*01:01 human CLIP103-117 peptide (PVSKMMATPMMQA) or negative control peptide; irrelevant peptide (NELSGEAHKDAL-GKLY) (MBL, Nagoya, Japan), and folding buffer. The folding reaction buffer solution was incubated at 37°C overnight, and then analyzed using HPLC with Superdex 200 column (GE Healthcare, Tokyo, Japan) to determine retention time of the HLA proteins.

The cytolytic activities of OCV-501-specific Th1 clones were estimated using the 51Cr-release assay [12]. The OCV-501-specific Th1 clones (6 clones) were established from 5 healthy donors (Clone R152-2 and P91-1 were from the same donor), and each clone was confirmed to have one HLA-class II restriction using various HLA-class II-bearing peptide-pulsed/un-pulsed B-LCLs. OCV-501-specific Th1 clones (effector) and 51Cr-labeled B-LCLs pulsed with/without OCV-501 (target) were tested at various effector/target (E/T) ratios (40:1, 20:1, and 10:1). At the end of the culture period, 50 μL of each supernatant was collected and radioactivity was calculated using TopCount NXT™ (PerkinElmer, Waltham, US). The percentage of specific lysis of target cells was determined as follows: (experimental count – spontaneous count)/(total count – spontaneous count) × 100 (%).

Clinical study

Study design

This was an open label, multi-center, phase 1 trial. A traditional 3+3 study design was used, with cohorts of three
to six patients. If one of the three patients experienced a dose-limiting toxicity (DLT) in the cohort, up to three patients would be enrolled at the same dosage level. If two or more patients experienced a DLT, no further dose escalation would be performed and additional patients were to be enrolled at a lower dose, to confirm the maximum tolerated dose (MTD). The MTD was defined as the highest dose at which none of the first three patients or one of up to six patients of total experienced a DLT in the cohort.

Patients

Older patients (≥60 years) with AML participated in this study. The eligibility criteria were that patients must have achieved their first CR with an induction regimen and completed standard consolidation therapy, and have been identified as WT1 mRNA positive, with one of the following HLA class II types: HLA-DRB1*01:01, *04:05, *15:01, *15:02, *08:03, or *09:01. Patients with myelodysplastic syndrome apparently evolved into AML and patients with AML accompanied by t(15;17)(q22;q12), (PML/RARalpha) were excluded. Patients scheduled for bone marrow transplantation, taking immunosuppressants and adrenal cortical steroids exceeding the acceptable therapeutic doses, with autoimmune diseases or with a medical history of active autoimmune diseases, and immunocompetent patients were excluded. HLA genotyping was performed using a PCR-based typing method [27].

Drug administration

OCV-501 emulsified with Montanide ISA 51 adjuvant for injection (Seppic Inc., Paris, France) was administered subcutaneously weekly for 4 weeks (day 1, day 8, day 15, and day 22). In each cohort, the first administration of the subsequent patient was allowed only after the second administration of the first patient had been completed. End of treatment and post-treatment examinations were performed after 1 week (on day 29) and 4 weeks (on day 50) from the last administration of OCV-501, respectively. The trial consisted of 3 cohorts at a dose of 0.3 mg in cohort 1, 1 mg in cohort 2, and 3 mg in cohort 3 which is in the range of 0.1 to 10 mg/body that is generally known to have no sign of dose dependency in immunological evaluations [28]. Administration commenced with cohort 1 and progressed to cohorts 2 and 3, depending on the assessment for DLT in the preceding cohort.

Safety and efficacy assessments in patients

Safety and tolerability of OCV-501 were operationalized as adverse events, clinical laboratory test, Eastern Cooperative Oncology Group performance status, vital signs (blood pressure, pulse rate, body temperature), body weight, 12-lead ECG, pulse oximetry, chest X-ray, and observation of the administration site. These adverse events were defined as treatment-emergent adverse events (TEAEs) and determined using the National Cancer Institute Common Terminology Criteria for Adverse Events score, version 4.0. DLT was the primary endpoint and determined based on adverse events.

As the efficacy variables, outcomes were evaluated by relapse of AML when assessed according to the International Working Group response criteria [29]. To monitor the minimal residual disease, WT1 mRNA level in peripheral blood was measured on day 1 (screening) and day 29 (end of treatment) and then once a month until morphological relapse. Peripheral blood levels of WT1 mRNA were measured using a WT1 mRNA Assay Kit ‘Otsuka’ (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan). RNA was extracted using the QIAamp RNA Blood Mini Kit (QIAGEN GmbH, Hilden, Germany) and the PCR product level of WT1 was quantified. The cutoff value of WT1 mRNA for early detection of relapse of AML was 200-copy/μg RNA. If the value surpassed the cut-off value, the investigator judged the need for bone marrow examination based on the subject’s condition.

WT1 mRNA level, delayed-type hypersensitivity (DTH), anti-OCV-501 Ab titer, and total IgG were determined as exploratory endpoints. The immune response to OCV-501 was analyzed using a DTH skin reaction test at the screening visit (baseline), on day 29, and day 31. An aqueous solution of OCV-501 (0.1 mg) for injection without Montanide was administered intra-dermally at approximately the center of the forearm flexors of the subject, and redness and induration were assessed at 48 h after administration. Anti-OCV-501 Ab titer was evaluated experimentally using anti-OCV-501 IgG (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) in plasma by ELISA on day 1 and day 29. Total IgG was measured on day 1, day 29 and day 50 (post treatment) by immunoassay.

Statistical analysis

An ANOVA with repeated measures (crossover type) or Wilcoxon signed rank test was performed for proportion assessment between the groups. Dose dependencies were analyzed using the Dunnett test with randomized block design. A two-way ANOVA was performed on specific lysis data with the group and E/T ratio as factors. A two-tailed t test was used and the level of significance was set at 0.05. SAS software (release 9.1, SAS Institute Japan) was used for all analyses. Statistical analyses in clinical study were not performed.
Results

Pre-clinical pharmacology

Ex vivo induction and activation of OCV-501-specific helper T cells

From day 7 to day 14, OCV-501-specific Th1 cells were significantly expanded in OCV-501 culture using human PBMC of 20 healthy donors as shown in Fig. 1a, but not in solvent culture ($p=0.0005$). Among 18 of 20 PBMC cultures, OCV-501-specific Th1 cells were increased and showed HLA-class II restriction by blocking experiments with anti-HLA-DR Ab. However, these were blocked with neither anti-HLA-DQ Ab nor mouse IgG2a. The HLA-DR restriction was detected in 7 of 18 samples. HLA-DR-specific inhibition in a typical and representative data is shown in Fig. 1b. T-cell activation in the other 11 of 18 samples was not inhibited by anti-HLA-DR/anti-HAL-DQ antibodies. This suggests that OCV-501 would stimulate some types of its specific T-cells in HLA-DR-restricted, and others in HLA-DP-restricted manner. Significant dose-dependent T-cell activation was observed at 10 μg/mL and higher concentrations of OCV-501 in the 20 OCV-501-induced PBMC cultures (Fig. 1c). Helper activity of OCV-501 was confirmed using WT1-killer peptides. OCV-501 enhanced

![Graph](attachment:image.png)

**Fig. 1** Efficacy pharmacology studies of OCV-501 using PBMC from healthy donor. Th1: Type 1 T-helper, WT1: Wilms’ tumor 1. Induction of OCV-501-specific Th1 cells in PBMC (a). PBMC were cultured with OCV-501 (filled circle) or solvent (circle) (data are expressed as mean±SE; $n=20$, *$P<0.0058$: main effect in mixed model for repeated measures method, crossover type). The HLA class II-restriction of OCV-501-derived antigen stimulation was evaluated using OCV-501-specific T cells induced in PBMC by blockade with anti-HLA class II antibody (b) (data are expressed as mean±SD, triplicates). Dose-dependence of OCV-501 activation of specific T cells (c) (data are expressed as mean±SE; $n=20$, *$P<0.05$: randomized block design, Dunnett’s test). WT1-specific CTLs were increased by OCV-501 and OCV-501-specific T cells; changes in the number of WT1-126-specific CTLs following addition of OCV-501 (d) (data are expressed as proportions of 3 independent samples). Changes in the number of WT1-235mu-specific CTLs following addition of OCV-501 (e) (data are expressed as proportions of 8 independent samples)
the increase in WT1-126-specific CTLs in 3 out of 3 samples (Fig. 1d) and WT1-235mu-specific CTLs in 6 of 8 samples (Fig. 1e) in the presence of PBMC-derived OCV-501-specific Th1 cells and WT1-killer peptide (WT1-126 or WT1-235mu)-specific CTLs.

HLA class II-restriction and cytolytic activity of OCV-501-specific Th1 clones

OCV-501-specific Th1 clone, CloneR45-1, which was bearing HLA-DRB1*04:05 (+), produced IFN-γ, when stimulated with HLA-DRB1*04:05 (+) B-LCL as APC, which were pulsed with OCV-501, but not when stimulated with HLA-DRB1*04:05 (−) B-LCL (Fig. 2a). Similarly, IFN-γ production was only observed in OCV-501-specific Th1 clone, CloneP51-5, which were bearing HLA-DPB1*05:01 (+), when stimulated with HLA-DPB1*05:01 (+) B-LCLs as APC which were pulsed with OCV-501 as shown in Fig. 2b. Moreover, OCV-501 stimulated the OCV-501-specific Th1 clones in an HLA class II-restricted manner with various B-LCLs as APCs bearing the different HLA class II types, such as HLA-DRB1*01:01, DRB1*08:02, DRB1*08:03, DRB1*13:02, DRB1*14:03, DRB1*14:05, DRB1*15:02, DRB3*02:02, DQB1*04:01, and DPB1*09:01 (Supplementary Fig. 1). The HPLC retention time of each HLA protein was markedly delayed more than 0.1 min by mixing with OCV-501 as well as a positive control, while the addition of negative peptide did not change the retention time (Table 1). This suggested complex formation of OCV-501 with the protein products of HLA class II DRB1*09:01, DRB1*15:01, DRB1*15:02, and DRB4*01:01 alleles. The cytolytic activities of OCV-501-specific Th1 clones (6 clones) were estimated using the 51Cr-release assay. Significant OCV-501-specific cytolytic activities against OCV-501-pulsed and restriction-matched B-LCL cells were found in OCV-501-specific Th1 clones (Fig. 2c–h).

Clinical trial

Between October 2011 and February 2013, 13 patients from 4 study sites in Japan were enrolled in this trial. Of the 13 patients from whom written informed consent was obtained, 4 were specified as screen failures (2 patients did not match the HLA types in inclusion criteria, 1 patient had Grade 3 lab test abnormality and 1 patient had a relapse of AML). Nine evaluable patients were enrolled in this study (Table 2). The median age was 70 years (range, 62–74 years). Chemotherapy varied among these patients, however, all had completed the planned AML therapy at the time of vaccination and were in first CR according to standard criteria. All had evidence of a measurable WT1 transcript at screening. Each cohort consisted of 3 subjects and all subjects completed the planned 4 vaccinations with either a 0.3, 1 or 3 mg dose of OCV-501.

Safety assessment

Incidence of TEAEs is summarized in Table 3. There were neither deaths nor serious TEAEs during the treatment period. None of the subjects discontinued OCV-501 administration due to TEAE. Grade 3 TEAEs included lymphocyte count decreased and neutrophil count decreased (1 subject each) in the OCV-501 1-mg cohort and thrombocytopenia (1 subject) in the OCV-501 3-mg cohort. These events were considered unrelated to OCV-501. The incidence of drug-related TEAEs by system organ class and preferred term are presented in Table 3. Injection site reactions, including erythema, induration, mass, pain, and pruritus were observed in all subjects. However, all drug-related TEAEs were Grade 1 or 2 in severity. No DLT was observed in any of the 3 cohorts and the MTD was considered to be ≥3 mg. This suggests that OCV-501 is safe and tolerable.

Efficacy outcomes

None of the 9 subjects with AML had a relapse from the time of screening (day-14 to day-1) to the time of end-of-trial (day 29). In the blood smear examination, no blast cells were observed in any of the 9 subjects. The percentage of myeloblasts in the 9 subjects was less than 5% before and after OCV-501 vaccination (Supplementary Table 1). Expressed levels of WT1 mRNA at screening (day 1) and at the end of treatment (day 29) were <50–950 and <50–2400 copies/µg RNA, respectively (Table 4). Decreases in WT1 mRNA were found in 2 subjects in the OCV-501 1-mg cohort and 2 subjects in the 3-mg cohort. All subjects were tested for a DTH response. Redness with induration of >5 mm diameter was confirmed in 1 subject each in the 0.3-mg cohort and 3-mg cohort and redness without induration was observed in 2 subjects in the 0.3 mg cohort and 1 subject each in the 1-mg cohort and 3-mg cohort (Supplementary Table 2). Anti-OCV-501 IgG was negative in all subjects at end of treatment (day 29) (Table 4). Total IgG levels at screening (day 1), end of treatment (day 29), and post treatment (day 50) were 1097–1499, 1041–1601, and 1106–1725 mg/dL, respectively (Supplementary Table 3).

Discussion

OCV-501 is a synthetic helper peptide, which consists of the natural sequence derived from the WT1 protein [24]. It was demonstrated that OCV-501 significantly induced OCV-501-specific Th1 cells in PBMC from 20 healthy
donors. Using both the induced primary Th1 cells and the established Th1 clones, OCV-501 also activated the specific Th1 cells in a dose-dependent manner. Furthermore, OCV-501 increased WT1-killer peptide-specific CTLs in the presence of OCV-501-specific Th1 cells. OCV-501-specific Th1 clones demonstrated significant OCV-501-specific cytolytic activity against OCV-501-pulsed B-LCL cells. In addition, reports have shown that WT1$_{1332}$ (a WT1 helper peptide that has the same amino acid sequence as OCV-501)-specific Th1 clone and -specific TCR-transduced CD4$^+$ T cells were able to respond to WT1-transfected B-LCL and kill WT1$^+$ leukemic cells.

Fig. 2 Efficacy pharmacology studies of OCV-501 using various T cell clones. B-LCL B-lymphoblastoid cell line, Th1 Type 1 T-helper. HLA-restricted T-cell activation by OCV-501 using various human T-cell clones. As an index of T-cell activating effect, the produced IFN-$\gamma$ from OCV-501-specific Th1 clone was estimated in the culture of HLA-DRB1*04:05(+) or DRB1*04:05(−) B-LCL cells pulsed with or without OCV-501 [CloneR45-1: HLA-DRB1*04:05(+) (a), CloneP51-5: HLA-DPB1*05:01(+) (b)] (data are expressed as mean ± SD, triplicates, S; error bar was calculated by extrapolated data). Cytolytic activity of OCV-501-specific Th1 clones with various HLA class II-restriction (DRB1*04:05 restricted CloneR45-1: (c), DRB1*15:02 restricted CloneR152-2: (d), DRB1*15:02 restricted CloneR152-3: (e), DRB3*02:02 restricted CloneR322-4: (f), DPB1*05:01 restricted CloneP51-2: (g), DPB1*09:01 restricted CloneP91-1: (h)). For specific lysis, each OCV-501-specific Th1 clone was used as effector cells and B-LCL cells pulsed (filled circle) or not pulsed (circle) with OCV-501 were used as target cells (data are expressed as mean ± SD of triplicates, **P < 0.01, 2-way ANOVA, group effect: n = 3).
respectively [24, 30, 31]. It has been reported that HLA-DR molecules are highly expressed in AML cells [32]. Therefore, these pre-clinical results suggest that OCV-501 activates both direct and indirect antitumor (anti-leukemic) cellular immunity, including specific cytotoxic Th1 cells and WT1-peptide-specific CTL cells, however, it is necessary to confirm the cytolytic activity of OCV-501-specific Th1 cells against several AML-derived leukemic cell lines. HLA class II-restriction of helper peptides is generally not as strict as the HLA class I-restriction of killer peptides, since helper peptides can bind to a variety of HLA class II molecules with loose recognition [33].

### Table 1 Complex formation of HLA class II/peptide

| HLA class II | Form formation of complexes with various HLA class II molecules (change in HPLC retention time: Δmin) |
|--------------|--------------------------------------------------------------------------------------------------|
|              | Negative control \( ^b \) | Positive control \( ^c \) | OCV-501 |
| DRB1*04:05   | –                      | + (0.021) | + (0.461)  | + (0.470) |
| DRB1*01:01   | –                      | + (0.076) | + (0.298)  | + (0.317) |
| DRB1*01:02   | –                      | + (0.001) | + (0.128)  | + (0.180) |
| DRB1*01:01   | –                      | + (0.028) | + (0.418)  | + (0.525) |
| DRB1*08:03   | –                      | + (0.007) | + (0.128)  | + (0.358) |
| DRB1*09:01   | –                      | + (0.007) | + (0.285)  | + (0.325) |
| DRB4*01:01   | –                      | + (0.034) | + (0.132)  | + (0.180) |

\(^a\)Negative control (16-mer:NELSGEAHKDALGKLY)

\(^b\)Positive control (15-mer-CLIP:PVSKMRMATPLLMQA)

\(^c\)(<0.1), + (≥0.1)

### Table 2 Demographics

| Dose | Subject ID | Classification of acute myeloid leukemia | Sex | Age (years) | HLA-DRB1 Genotype | ECOG PS |
|------|------------|-----------------------------------------|-----|-------------|-------------------|--------|
| 0.3 mg | 001–00001 | Acute myeloid leukemia, not otherwise specified, AML without maturation | Female | 70 | 08:03 09:01 | 0 |
|           | 002–0001 | Acute myeloid leukemia, not otherwise specified, AML with maturation | Female | 62 | 04:05 04:06 | 0 |
|           | 002–0002 | Acute myeloid leukemia, not otherwise specified, AML with minimal differentiation | Male | 69 | 13:02 15:01 | 0 |
| 1.0 mg | 001–0002 | Acute myeloid leukemia, not otherwise specified, AML without maturation | Female | 65 | 01:01 15:02 | 0 |
|           | 002–0003 | Acute myeloid leukemia with recurrent genetic abnormalities, AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 | Male | 71 | 04:05 09:01 | 0 |
|           | 002–0004 | Acute myeloid leukemia with recurrent genetic abnormalities, AML with inv(16)(p13.1q22) or (t(16;16)(p13.1;q22); CBFB-MYH11 | Female | 72 | 09:01 14:54 | 0 |
| 3.0 mg | 001–0003 | Acute myeloid leukemia, not otherwise specified, AML with maturation | Male | 74 | 09:01 13:02 | 1 |
|           | 001–0004 | Acute myeloid leukemia, not otherwise specified, AML with maturation | Male | 73 | 04:05 04:06:01 | 0 |
|           | 002–0005 | Acute myeloid leukemia, not otherwise specified, AML with maturation | Male | 62 | 04:07 15:02 | 0 |

**AML** acute myeloid leukemia, **HLA** human leukocyte antigen, **ECOG PS** Eastern Cooperative Oncology Group, performance status

0: Fully active, able to carry on all pre-disease performance without restriction

1: Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work

2: Ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking h

3: Capable of only limited self-care, confined to bed or chair more than 50% of waking h

4: Completely disabled. Cannot carry on any self care. Totally confined to bed or chair

Cancer Immunol Immunother (2017) 66:851–863
Table 3 Incidence of drug-related treatment-emergent adverse events

| System organ class                                      | Preferred term                                      | 0.3 mg | 1 mg | 3 mg | Total |
|---------------------------------------------------------|-----------------------------------------------------|--------|------|------|-------|
|                                                          |                                                     | Grade 1 | Grade 2 | Grade 3–5 | Grade 1 | Grade 2 | Grade 3–5 | Grade 1 | Grade 2 | Grade 3–5 | N (%)   |
|                                                          |                                                     | N=3 | N=0 | N=0 | N=3 | N=0 | N=0 | N=3 | N=1 | N=0 | N=9 |
| General disorders and administration site conditions     |                                                     | 3 | 0 | 0 | 3 | 0 | 0 | 3 | 0 | 0 | 9 (100.0) |
| Injection site erythema                                  |                                                     | 3 | 0 | 0 | 3 | 0 | 0 | 3 | 0 | 0 | 9 (100.0) |
| Injection site induration                               |                                                     | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 7 (77.8) |
| Injection site mass                                     |                                                     | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Injection site pain                                     |                                                     | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Injection site pruritus                                  |                                                     | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 3 (33.3) |
| Investigations                                           |                                                     | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 (22.2) |
| Eosinophil count increased                              |                                                     | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Lymphocyte count decreased                              |                                                     | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 (11.1) |
| Neutrophil count decreased                              |                                                     | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 (11.1) |
| White blood cell count decreased                        |                                                     | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 (11.1) |
| Musculoskeletal and connective tissue disorders         |                                                     | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Joint swelling                                          |                                                     | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Nervous system disorders                                |                                                     | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 (22.2) |
| Headache                                                |                                                     | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Hypoesthesia                                            |                                                     | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Skin and subcutaneous tissue disorders                 |                                                     | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |
| Erythema                                                |                                                     | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) |

MedDRA version 14.0
study, OCV-501 also showed binding to and/or activation of T cell via at least 15 HLA class II molecules. Expression frequencies of these HLA class II molecules in Asian including Japanese, Caucasian, and African black were 83.8–98.8, 79.2–80.2, and 67.7–68.8%, respectively [34]. This suggests that OCV-501 can be used not only for Japanese patients but also for worldwide cancer patients.

Much attention has been paid to the development of helper peptides [22, 23], since helper peptide vaccination induces and activates cancer-specific Th1 cells, which are the control tower for cancer immunity, and increases the antitumor effect by inducing the antibodies that stimulate proliferation and activation of CTLs, activation of APCs, and incorporation of cancer cells through IL-2 and IFN-γ production. Several approaches have been investigated to potentiate the clinical responses of killer peptide-based vaccines [35, 36]. Mixture of killer and helper peptides and a long helper peptide containing class I and class II epitope regions demonstrated to respond to both CD4+ and CD8+ T cells [17, 37–42]. Potential clinical benefits of the multiple peptide vaccine were also observed in survival curves in patients with AML compared with unvaccinated controls [40]. These observations suggest that the multiple peptides including killer/helper epitopes seems to be one of the promising strategies for activating both CD4+ Th1 and CD8+ CTL responses. On the other hand, vaccination with a mixture of 6 HLA-DR-restricted melanoma helper peptides induced both specific Th1-dominant CD4+ T cell responses and Ab responses, associated with improved overall survival among patients with metastatic melanoma [43, 44]. The survival strongly correlated with early Ab response and/or with early T-cell response [44]. There was a hierarchy of immunodominance of helper peptides and no evidence that peptide length or the type of source tumor antigen predicted immunodominance. These results would reveal that only one single immunodominant helper peptide can elicit both specific Th1-dominant CD4+ T cell responses and Ab responses, suggesting that helper peptide would be a potent cancer vaccine without combination with killer and/or helper peptides [45, 46]. Additionally, easy formulation of a single helper peptide rather than multiple peptides vaccine should be an additional advantage of OCV-501 from drug development point of view. Also, OCV-501, single WT1-helper peptide, had helper peptide activities including wide-range HLA-class II restrictions and cytolytic CD4+ T cell induction which might be stronger than that of the other TAA-helper peptides.

We conducted an open label, multi-center, phase 1 trial of OCV-501 to evaluate the safety and tolerability in older AML patients in CR. Nine patients were enrolled and all completed the study. All doses of OCV-501 administered subcutaneously 4 times every 4 weeks were well-tolerated and safe, and the MTD was considered to be ≥3 mg. Injection site reactions were observed in all patients at all dosage levels. These might have been due to the Montanide used as an adjuvant, the frequent side effects of which are

| Dose | Subject ID | Time point | WT1 mRNA (copy/µg RNA) | Anti-OCV-501 antibody concentration (ng/mL) |
|------|------------|------------|-------------------------|---------------------------------------------|
| 0.3 mg | 001–0001 | Day 1 | <50 | Negative |
|       |          | End of treatment | 75 | Negative |
|       | 002–0001 | Day 1 | 950 | Negative |
|       |          | End of treatment | 2400 | Negative |
|       | 002–0002 | Day 1 | <50 | Negative |
|       |          | End of treatment | 66 | Negative |
| 1.0 mg | 001–0002 | Day 1 | <50 | Negative |
|       |          | End of treatment | 57 | Negative |
|       | 002–0003 | Day 1 | 64 | Negative |
|       |          | End of treatment | <50 | Negative |
|       | 002–0004 | Day 1 | 120 | Negative |
|       |          | End of treatment | 69 | Negative |
| 3.0 mg | 001–0003 | Day 1 | 150 | Negative |
|       |          | End of treatment | 120 | Negative |
|       | 001–0004 | Day 1 | 340 | Negative |
|       |          | End of treatment | <50 | Negative |
|       | 002–0005 | Day 1 | 51 | Negative |
|       |          | End of treatment | 59 | Negative |

**WT1** Wilms' Tumor 1 gene
well known to include inflammatory reactions, granulomas and ulcers at the injection site [47]. Clinical efficacies and immunological responses were unconfirmed in this clinical study. However, no patients relapsed during the study. All the patients provided informed consent to continue further vaccination with OCV-501 in an extension trial to evaluate the safety and efficacy of continuous administration of OCV-501. Immune response in DTH with induration of >5 mm diameter was observed in 2 patients, suggesting that these might be clues to clinical efficacy due to OCV-501 vaccination. Anti-OCV-501 IgG formation was found in rats and dogs in pre-clinical studies. Although anti-OCV-501 Ab was not detected during the study, this appeared in some patients in the follow-up period after the study (data not shown). These data might also support immune responses to OCV-501 suggesting the rationale to use the dose range of this study in future studies.

In conclusion, OCV-501, a WT1 helper peptide, induced OCV-501-specific Th1 responses dose-dependently and stimulated helper activity of the specific Th1 cells in PBMC from healthy donors in an HLA class II-restricted manner. OCV-501-specific Th1 clones showed significant OCV-501-specific cytolytic activity against B-LCL cells. In this phase 1 clinical trial, OCV-501, administered subcutaneously once a week for 4 weeks to older patients with AML, was well-tolerated and safe with a considerable MTD of ≥3 mg. Further clinical studies of OCV-501 in patients with AML should be considered to confirm its safety, and efficacy.

Acknowledgements All participating institutes received financial support from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). The efficacy and Safety Data Committee, Dr. Kiyohiko Hatake of The Cancer Institute Hospital, Dr. Kenshi Suzuki of the Japanese Red Cross Medical Center, and Prof. Masahiro Kizaki of Saitama Medical Center, Saitama Medical University, advised by evaluating the safety and efficacy. Prof. Nobutaka Kawai of International Medical Center, Saitama Medical University and Dr. Yasunori Ueda of Kure-shiki Central Hospital participated in the clinical part. The pre-clinical pharmacology part was conducted in Tokushima Microbiological Research Institute, Otsuka Pharmaceutical. Hiroshi Kubo, Masayoshi Sato, Ryuki Kitamoto, Isao Shibuya, Yoshihiro Goto, Fusako Iwata, and Yasukazu Ohmoto of Microbiological Research Institute, Otsuka Pharmaceutical performed the pre-clinical pharmacology studies and established an examination system for clinical samples. Masaru Kamishohara and Kentaro Ouchi of Medical Affairs, Otsuka Pharmaceutical managed a medical writing service vendor. We thank Dr. Tetsuji Asao (SunFlare Co., Ltd., Tokyo, Japan) for medical writing service, which was funded by Otsuka Pharmaceutical.

Compliance with ethical standards

Funding This study was funded by Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan).

Conflict of interest Kazuyuki Toga and Shinji Sogo are employees of Otsuka Pharmaceutical. Yuji Heike received a consulting fee from Otsuka Pharmaceutical as the Medical Adviser of this study. Yukio Kobayashi received research funding from Otsuka Pharmaceutical, Celgene, CMIC (Tokyo, Japan), Pfizer, Astellas Pharma, Boehringer Ingelheim, and AMGEN. Toru Sakura received research funding from Otsuka Pharmaceutical. Syuichi Miyawaki declares no conflict of interest.

Ethical approval The clinical study protocol and informed consent form were approved by the institutional review board at each study site. The clinical study was conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference on Harmonization of Good Clinical Practice guidelines, and locally applicable laws and regulations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. O’Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E et al (2012) Acute myeloid leukemia. J Natl Compr Canc Netw 10:984–1021
2. Burnett A, Wetzler M, Löwenberg B (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487–494. doi:10.1200/JCO.2010.30.1820
3. Grosso DA, Hess RC, Weiss MA (2015) Immunotherapy in acute myeloid leukemia. Cancer 121:2689–2704. doi:10.1002/cncr.29378
4. Greiner J, Döhner H, Schmitt M (2006) Cancer vaccines for patients with acute myeloid leukemia—definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91:1653–1661
5. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337. doi:10.1158/1078-0432.CCR-09-0737
6. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al (1990) Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60:509–520
7. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071–3079
8. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y et al (1997) Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405–1412
9. Nakatsuka S, Oji Y, Horiiuchi T, Kanda T, Kitagawa M, Takeuchi T et al (2006) Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19:804–814. doi:10.1038/modpathol.3800588
10. Sugiyama H (1998) Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma 30:55–61. doi:10.3109/10428199809050929
11. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T et al (1996) Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides:
implications for the involvement of WT1 in leukemogenesis. Blood 87:2878–2884
12. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I et al (2005) Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 106:1415–1418. doi:10.1182/blood-2005-01-0413
13. Oya Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al (2004) Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101:13885–13890. doi:10.1073/pnas.0405884101
14. Ochselreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D et al (2011) “Wilms Tumor Protein 1” (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother 34:85–91. doi:10.1097/CJI.0b013e3181f3ec5c
15. Di Stasi A, Jimenez AM, Minagawa K, Al-Obaidi M, Rezvani K et al (2015) Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol 6:36. doi:10.3389/fimmu.2015.00336
16. Oya Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H (2008) WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20:211–220. doi:10.1016/j.coi.2008.04.009
17. Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Tagushi Y et al (2012) First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 103:150–153. doi:10.1111/j.1349-7006.2011.02106.x
18. Busse A, Letsch A, Scheibenbogen C, Nonnenmacher A, Ochselreither S, Thiel E et al (2010) Mutation or loss of Wilms’s tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination. J Transl Med 8:5. doi:10.1186/1479-5876-8-5
19. Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Lee RQ et al (2011) Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 96:432–440. doi:10.3324/haematol.2010.031674
20. Marzo AL, Kinneer BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW et al (2000) Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 165:6047–6055
21. Janssen EM, Lemmens EE, Wolfe T, Christen U, van Herrath MG, Schoenberger SP (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852–856. doi:10.1038/nature01441
22. Galaline J, Borg C, Godet Y, Adotévi O (2015) Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines (Basel) 3:490–502. doi:10.3390/vaccines3030490
23. Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M et al (2010) A new era in anticancer peptide vaccines. Cancer 116:2071–2080. doi:10.1002/cncr.24988
24. Fujiki F, Oka Y, Kawakami M, Kawakatsu M, Nakajima H et al (2007) Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother 30:282–293. doi:10.1097/jiol.0b013e3180115394
25. Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M (2012) Phase I trial of Wilms’ Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anti-cancer Res 32:2263–2269
26. Sato AK, Zarutsksie JA, Rushe MM, Lomakin A, Natarajan SK, Sadegh-Nasser S et al (2000) Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem 275:2165–2173
27. Shichishima T, Okamoto M, Ikeda K, Kaneshige T, Sugiyama H, Terasawa T et al (2002) HLA class II haplotype and quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood 100:22–28
28. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL et al (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327
29. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425. doi:10.1182/blood-2005-10-1419
30. Lin Y, Fujiki F, Katsuhara A, Oya Y, Tsuboi A, Aoyama N et al (2013) HLA-DBP1*05:01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells. J Immunother 36:159–170
31. Katsuhara A, Fujiki F, Aoyama N, Tani S, Morimoto S, Oka Y et al (2015) Transduction of a novel HLA-DRB1*04:05-restricted, WT1-specific TCR gene into human CD4+ T Cells confers killing activity against leukemia cells. Anti-cancer Res 35:1251–1262
32. Webber BA, Cushing MM, Li S (2008) Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia. Int J Clin Exp Pathol 1:124–133
33. Schroers R, Shen L, Rollins L, Rooney CM, Slawin K, Sonderrup G et al (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743–4755
34. Tsuji K, Aizawa M, Sasazuki T (1992) HLA 1991: proceedings of the Eleventh International Histocompatibility Workshop and Conference, held in Yokohama, Japan. Oxford University Press, Oxford
35. Oya Y, Sugiyama H (2010) WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy 2:591–594. doi:10.2217/imt.10.58
36. Yamada A, Sasada T, Noguchi M, Itoh K (2013) Next-generation peptide vaccines for advanced cancer. Cancer Sci 104:15–21. doi:10.1111/cas.12050
37. Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M et al (2006) Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 55:850–860. doi:10.1007/S00262-005-0071-0
38. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S et al (2010) WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 59:1467–1479. doi:10.1007/s00262-010-0871-8
39. Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD et al (2011) Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide ISA51 and CpG7909. Cancer Immunol Immunother 60:161–171. doi:10.1007/s00262-010-0929-7
40. Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R et al (2015) WT1 vaccination in AML and MDS: a pilot trial with synthetic analog peptides. Am J Hematol 90:602–607. doi:10.1002/ajh.24014
41. Masuko K, Wakita D, Tagushi Y, Kita T, Kitamura H, Nishimura T (2015) Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological
analysis of vaccine efficacy. Immunol Lett 163:102–112. doi:10.1016/j.imlet.2014.11.016
42. May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH et al (2007) Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 13:4547–4555. doi:10.1158/1078-0432.CCR-07-0708
43. Hu Y, Petroni GR, Olson WC, Czarkowski A, Smolkin ME, Grosh WW et al (2014) Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother 63:779–786. doi:10.1007/s00262-014-1551-x
44. Reed CM, Cresce ND, Mauldin IS, Stingluff CL Jr, Olson WC (2015) Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival. Clin Cancer Res 21:3879–3887. doi:10.1158/1078-0432.CCR-15-0233
45. Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54:721–728. doi:10.1007/S00262-004-0653-2
46. Müller L, Knights A, Pawelec G (2003) Synthetic peptides derived from the Wilms’ tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. Hematol J 4:57–66. doi:10.1038/sj.thj.6200220
47. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:488–496. doi:10.1111/j.0818-9641.2004.01272.x